Drug · CHEMBL83
TAMOXIFEN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. TAMOXIFEN. Drugs and targets, record CHEMBL83. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL83
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ESR1 | Estrogen receptor | Estrogen receptor alpha modulator | MODULATOR | https://conductscience.org/library/genes/2099 |
Source ChEMBL
Diseases58
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 58Source Open Targets
See all 58 diseasesTrials323
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 2 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00310180 | Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) | Phase 3 | 10,273 | 2019-03-12 | tamoxifen | Its name | ClinicalTrials.gov |
| NCT00036270 | Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane | Phase 3 | 9,779 | 2009-12-04 | tamoxifen | Its name | ClinicalTrials.gov |
| NCT00003782 | Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes | Phase 3 | 5,351 | 2012-10-31 | tamoxifen | Its name | ClinicalTrials.gov |
| NCT00053898 | Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy | Phase 3 | 3,104 | 2018-03-12 | tamoxifen | Its name | ClinicalTrials.gov |
| NCT00066690 | Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer | Phase 3 | 3,066 | 2016-09-22 | tamoxifen | Its name | ClinicalTrials.gov |
| NCT00072462 | Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ | Phase 3 | 2,980 | 2024-09-19 | tamoxifen | Its name | ClinicalTrials.gov |
| NCT00295646 | Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid | Phase 3 | 1,803 | 2024-03-15 | tamoxifen | Its name | ClinicalTrials.gov |
| NCT00687102 | Cognition in the Study of Tamoxifen and Raloxifene | Phase 3 | 1,498 | 2018-01-23 | tamoxifen | Its name | ClinicalTrials.gov |
| NCT03346200 | Low Dose Tamoxifen for Mammographic Density Reduction | Phase 2 | 1,440 | 2025-03-07 | tamoxifen | Its name | ClinicalTrials.gov |
| NCT00201851 | Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer | Phase 3 | 740 | 2015-04-29 | tamoxifen | Its name | ClinicalTrials.gov |
1 to 10 of 323
See all 323 trialsComparisons in its trials58
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Tamoxifen Followed by Exemestane vs Exemestane: serious adverse events | 784 of 4,814 | 831 of 4,852 | 9,666 | NCT00036270 | Trial comparisons |
| Group 1: Tamoxifen + Anastrozole Placebo vs Group 2: Anastrazole + Tamoxifen Placebo: serious adverse events | 73 of 1,535 | 62 of 1,535 | 3,070 | NCT00053898 | Trial comparisons |
| Anastrozole vs Tamoxifen: Number of Breast Cancer Deaths | 3 of 1,449 | 3 of 1,489 | 2,938 | NCT00072462 | Trial comparisons |
| Anastrozole vs Tamoxifen: Number of Participants With ER- Breast Cancer Recurrence | 24 of 1,449 | 15 of 1,489 | 2,938 | NCT00072462 | Trial comparisons |
| Anastrozole vs Tamoxifen: Number of Participants With Breast Cancer Recurrence, Including Recurrent DCIS and New Contralateral Tumours | 103 of 1,449 | 120 of 1,489 | 2,938 | NCT00072462 | Trial comparisons |
| Anastrozole vs Tamoxifen: Number of Participants With ER+ Breast Cancer Recurrence, Including Recurrent DCIS and New Contralateral Tumours | 58 of 1,449 | 82 of 1,489 | 2,938 | NCT00072462 | Trial comparisons |
| Anastrozole vs Tamoxifen: Number of Non-breast Cancer Deaths | 59 of 1,449 | 65 of 1,489 | 2,938 | NCT00072462 | Trial comparisons |
| Anastrozole vs Tamoxifen: deaths from any cause | 62 of 1,449 | 69 of 1,489 | 2,938 | NCT00072462 | Trial comparisons |
| Anastrozole vs Tamoxifen: serious adverse events | 333 of 1,449 | 371 of 1,489 | 2,938 | NCT00072462 | Trial comparisons |
| Star Participants Assigned to Tamoxifen vs Star Participants Assigned to Raloxifene: serious adverse events | 0 of 733 | 0 of 765 | 1,498 | NCT00687102 | Trial comparisons |
1 to 10 of 58
See all 58 comparisons in its trialsPapers from its trials342
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials6
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Category Fluency | 1 | 0 | ConductCognition |
| Digit Span Test | 1 | 0 | ConductCognition |
| Finger Tapping Task | 1 | 0 | ConductCognition |
| Go/No-Go Task | 1 | 0 | ConductCognition |
| Verbal Fluency | 1 | 0 | ConductCognition |
| Verbal Learning | 1 | 1 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL83
GET https://conductscience.org/api/drugs/v1/CHEMBL83/diseases?page=2